Skip to main content
SpringerLink
Log in

Choosing a Target for Nuclear Imaging or Targeted Radiotherapy

  • Chapter
  • First Online:
Radiopharmaceutical Chemistry

  • 4364 Accesses

Abstract

Single-photon emission computerized tomography (SPECT) and positron-emission tomography (PET) imaging are highly sensitive techniques that allow for the non-invasive detection, quantitation, and response monitoring of a broad array of diseases through target visualization and kinetic modeling. The selection of a target for nuclear imaging requires a deep understanding of the disease process and physiological changes that are to be evaluated. The target itself may be protein expressed on cells of a particular organ, a receptor on circulating blood cells, or a biochemical or metabolic pathway in cells throughout the body. Targeted radiotherapy has emerged as a highly promising modality across a range of diseases, and the selection of targets for therapy is dependent on the radionuclide utilized, the biology of target expression, and the sensitivity of cells to radiation treatment. This chapter reviews the basis of target selection for radiopharmaceuticals and provides examples of the successful clinical use of targeted imaging and therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Edwards CI. Tumor localizing radionuclides in retrospect and prospect. Semin Nucl Med. 1979;3:186–9.

    Article  Google Scholar 

  2. Ice RD. History of medical radionuclide production. Health Phys. 1995;69(5):721–7.

    Article  CAS  PubMed  Google Scholar 

  3. Ell P, Gambhir S, editors. Nuclear medicine in clinical diagnosis and treatment. 3rd ed. London: Churchill Livingstone; 2004.

    Google Scholar 

  4. Thul PJ, Ã…kesson L, Wiking M, Mahdessian D, Geladaki A, AitBlal H, et al. A subcellular map of the human proteome. Science. 2017;356(6340). pii: eaal3321.

    Google Scholar 

  5. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74.

    Article  CAS  PubMed  Google Scholar 

  6. Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HP. Kinase-target cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Cardon LR, Harris T. Precision medicine, genomics and drug discovery. Hum Mol Genet. 2016;25(R2):R166–72.

    Article  CAS  PubMed  Google Scholar 

  8. Weber J, Haberkorn U, Mier W. Cancer stratification by molecular imaging. Int J Mol Sci. 2015;16(3):4918–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kenny LM, Aboagye EO. Clinical translation of molecular imaging agents used in PET studies of cancer. Adv Cancer Res. 2014;124:329–74.

    Article  CAS  PubMed  Google Scholar 

  10. Gandal MJ, Leppa V, Won H, Parikshak NN, Geschwind DH. The road to precision psychiatry: translating genetics into disease mechanisms. Nat Neurosci. 2016;19(11):1397–407.

    Article  CAS  PubMed  Google Scholar 

  11. Varley J, Brooks DJ, Edison P. Imaging neuroinflammation in Alzheimer’s disease and other dementias: recent advances and future directions. Alzheimers Dement. 2015;11(9):1110–20.

    Article  PubMed  Google Scholar 

  12. Osborn EA, Kessinger CW, Tawakol A, Jaffer FA. Metabolic and molecular imaging of atherosclerosis and venous thromboembolism. J Nucl Med. 2017;58(6):871–7.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Villemagne VL, Doré V, Bourgeat P, Burnham SC, Laws S, Salvado O, et al. Aβ-amyloid and tau imaging in dementia. Semin Nucl Med. 2017;47(1):75–88.

    Article  PubMed  Google Scholar 

  14. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87.

    Article  CAS  PubMed  Google Scholar 

  15. Orcutt KD, Adams GP, Wu AM, Silva MD, Harwell C, Hoppin J, et al. Molecular simulation of receptor occupancy and tumor penetration of an antibody and smaller scaffolds: application to molecular imaging. Mol Imaging Biol. 2017;19(5):656–64.

    Article  CAS  PubMed  Google Scholar 

  16. Ciprotti M, Chong G, Gan HK, Chan A, Murone C, MacGregor D, et al. Quantitative intratumoral microdistribution and kinetics of (131)I-huA33 in patients with colorectal carcinoma. EJNMMI Res. 2014;4:22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol. 2017;14(11):695–707.

    Article  CAS  PubMed  Google Scholar 

  19. van Isselt JW, Gast B-d. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Grave’s disease. Hell J Nucl Med. 2010;13(1):2–5.

    PubMed  Google Scholar 

  20. Goldstein JL, Anderson RGW, Brwon MS. Coated pits, coated vesicles and receptor-mediated endocytosis. Nature. 1979;279:679–85.

    Article  CAS  PubMed  Google Scholar 

  21. Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol. 2009;10:609–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38(5):696–701.

    Article  CAS  PubMed  Google Scholar 

  23. Luster M, Pfestroff A, Hänscheid H, Verburg FA. Radioiodine therapy. Semin Nucl Med. 2017;47(2):126–34.

    Article  PubMed  Google Scholar 

  24. Puranik AD, Kulkarni HR, Baum RP. Companion diagnostics and molecular imaging. Cancer J. 2015;21(3):213–7.

    Article  CAS  PubMed  Google Scholar 

  25. Yordanova A, Eppard E, Kürpig S, Bundschuh RA, Schönberger S, Gonzalez-Carmona M, et al. Theranostics in nuclear medicine practice. Onco Targets Ther. 2017;10:4821–8.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Braband H. High-valent technetium chemistry – new opportunities for radiopharmaceutical developments. J Label Compd Radiopharm. 2014;57(4):270–4.

    Article  CAS  Google Scholar 

  27. SmitDuijzentkunst DA, Kwekkeboom DJ, Bodei L. Somatostatin receptor-2 targeting compounds. J Nucl Med. 2017;58(Suppl 2):10S–6S.

    Google Scholar 

  28. Oliveira BL, Caravan P. Peptide-based fibrin-targeting probes for thrombus imaging. Dalton Trans. 2017;46(42):14488–508.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Bjornmalm M, Thurecht KJ, Michael M, Scott AM, Caruso F. Bridging bio-nano science and cancer nanomedicine. ACS Nano. 2017;11(10):9594–613.

    Article  CAS  PubMed  Google Scholar 

  30. Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev. 2010;110(5):3087–111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Katritch V, Cherezov V, Stevens RC. Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 2013;53:531–56.

    Article  CAS  PubMed  Google Scholar 

  32. Schottelius M, Wester H-J. Molecular imaging targeting peptide receptors. Methods. 2009;48(2):161–77.

    Article  CAS  PubMed  Google Scholar 

  33. Parakh S, Parslow AC, Gan HK, Scott AM. Antibody-mediated delivery of therapeutics for cancer therapy. Expert Opin Drug Deliv. 2016;13(3):401–19.

    Article  CAS  PubMed  Google Scholar 

  34. Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, et al. Theranostics using antibodies and antibody-related therapeutics. J Nucl Med. 2017;58(Suppl 2):83S–90S.

    Article  CAS  PubMed  Google Scholar 

  35. Goedert M, Yamaguchi Y, Mishra SK, Higuchi M, Sahara N. Tau filaments and the development of positron emission tomography tracers. Front Neurol. 2018;9:70.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain Parkinsonism: a systematic review. EJNMMI Res. 2015;5:12.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Elsinga P, Ishiwata K, Hatano K. PET tracers for imaging the dopaminergic system. Med Chem. 2006;13(18):2139–53.

    CAS  Google Scholar 

  38. Slifstein M. Abi-Dargham. Recent developments in molecular brain imaging of neuropsychiatric disorders. Semin Nucl Med. 2017;47(1):54–63.

    Article  PubMed  Google Scholar 

  39. Kassenbrock A, Vasdev N, Liang SH. Selected PET radioligands for ion channel linked neuroreceptor imaging: focus on GABA, NMDA and nACH receptors. Curr Top Med Chem. 2016;16(16):1830–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Meyer PM, Tiepolt S, Barthel H, Hesse S, Sabri O. Radioligand imaging of α4α2* nicotinic acetylcholine receptors in Alzheimer’s disease and Parkinson’s disease. Q J Nucl Med Mol Imaging. 2014;58(4):376–86.

    CAS  PubMed  Google Scholar 

  41. Denora N, Natile G. An updated view of the translocator protein (TSPO). Int J Mol Sci. 2017;18(12). pii. E2640.

    Google Scholar 

  42. Alam MM, Lee J, Lee SY. Recent progress in the development of TSPO PET ligands for neuroinflammation imaging in neurologic diseases. Nucl Med Mol Imaging. 2017;51(4):283–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Shaw SY. Molecular imaging in cardiovascular disease: targets and opportunities. Nat Rev Cardiol. 2009;6:567–79.

    Article  CAS  Google Scholar 

  44. Underwood SR, de Bondt P, Flotats A, Marcasa C, Pinto F, Schaefer W, Verberne HJ. The current and future status of nuclear cardiology: a consensus report. Eur Heart J. 2014;15:949–55.

    Google Scholar 

  45. Travin MI. Current clinical applications and next steps for cardiac innervation imaging. Curr Cardiol Rep. 2017;19(1):1.

    Article  PubMed  Google Scholar 

  46. Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S126–38.

    Article  PubMed  CAS  Google Scholar 

  47. Bala G, Blykers A, Xavier C, Descamps B, Broisat A, Ghezzi C, et al. Argeting of vascular cell adhesion molecule-1 by 18F-labelled nanobodies for PET/CT imaging of inflamed atheroscerotic plaques. Eur Heart J Cardiovac Imaging. 2016;17(9):1001–8.

    Article  Google Scholar 

  48. Laufer EM, Winkens HM, Corsten MF, Reutelingsperger CP, Narula J, Hofstra L. PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled Annexin A5. Q J Nucl Med Mol Imaging. 2009;53(1):26–34.

    CAS  PubMed  Google Scholar 

  49. Annovazzi A, Bonanno E, Arca M, D’Alessandria C, Marcoccia A, Spagnoli LG, et al. 99mTc-interleukin-2 scintigraphy for the in vivo detection of vulnerable atherosclerotic plaques. Eur J Nucl Med Mol Imaging. 2006;33(2):117–26.

    Article  CAS  PubMed  Google Scholar 

  50. Hanahan D, Weinberg RA. Hallmarks of cancer. Cell. 2011;144(5):646–74.

    Article  CAS  PubMed  Google Scholar 

  51. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG in oncology. J Nucl Med. 2008;49:480–508.

    Article  PubMed  Google Scholar 

  52. Zhu A, Lee D, Shim H. Metabolic PET imaging in cancer detection and therapy response. Semin Oncol. 2011;38(1):55–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, et al. Appropriate use criteria for 18F-FDG PET/CT in restaging and treatment response assessment of malignant disease. J Nucl Med. 2017;58(12):2026–37.

    Article  CAS  PubMed  Google Scholar 

  54. Van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012;33(3):607–15.

    Article  CAS  PubMed  Google Scholar 

  55. Peck M, Pollack HA, Friesen A, Muzi M, Shoner SC, Shankland EG, et al. Applications of PET imaging with the proliferation marker [18F]-FLT. Q J Nucl Med Mol Imaging. 2015;59(1):95–104.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016;18(3):426–34.

    Article  CAS  PubMed  Google Scholar 

  57. Lee ST, Scott AM. Hypoxia imaging with 18F-Fluoromisonidazole. Semin Nucl Med. 2007;37(6):451–61.

    Article  PubMed  Google Scholar 

  58. Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer. 2015;112:238–50.

    Article  CAS  PubMed  Google Scholar 

  59. Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, et al. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res. 2005;11(13):4818–26.

    Article  CAS  PubMed  Google Scholar 

  60. Khajornjiraphan N, Thu NA, Chow PKH. Yttrium-90 microspheres: a review of its emerging clinical indications. Liver Cancer. 2015;4(1):6–15.

    Article  CAS  PubMed  Google Scholar 

  61. Knut L. Radiosynovectomy in the therapeutic management of arthritis. World J Nucl Med. 2015;14(1):10–5.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, NETTER-1 Trial Investigators, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52–60.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, et al. Curative multicycleradioimmunotherapy monitored by quantitative SPECT/CT based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer. J Nucl Med. 2017;58(11):1735–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Florimonte L, Dellavedova L, Maffiolo LS. Radium-223 dichoride in clinical practice: a review. Eur J Nucl Med Mol Imaging. 2016;43(10):1896–909.

    Article  CAS  PubMed  Google Scholar 

  66. Marcu L, Bezak E, Allen BJ. Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Crit Rev Oncol. 2018;123:7–20.

    Article  Google Scholar 

Download references

Acknowledgments

The authors acknowledge support from NHMRC (grants 1092788, 1143710, 1084178), Cancer Council Victoria, and Operational Infrastructure from the Victorian Government.

Author information

Authors and Affiliations

  1. Department of Molecular Imaging and Therapy, Austin Hospital, Heidelberg, VIC, Australia

    Andrew M. Scott, Sze Ting Lee & Salvatore U. Berlangieri

  2. Tumour Targeting Laboratory, Olivia-Newton John Cancer Research Institute, and La Trobe University, Melbourne, VIC, Australia

    Andrew M. Scott

  3. University of Melbourne, Melbourne, VIC, Australia

    Andrew M. Scott

  4. Tumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia

    Yit Wooi Goh & Sze Ting Lee

Authors
  1. Andrew M. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yit Wooi Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sze Ting Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Salvatore U. Berlangieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew M. Scott .

Editor information

Editors and Affiliations

  1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Jason S. Lewis

  2. Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

    Albert D. Windhorst

  3. Department of Chemistry, Hunter College, City University of New York, New York, NY, USA

    Brian M. Zeglis

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Scott, A.M., Goh, Y.W., Lee, S.T., Berlangieri, S.U. (2019). Choosing a Target for Nuclear Imaging or Targeted Radiotherapy. In: Lewis, J., Windhorst, A., Zeglis, B. (eds) Radiopharmaceutical Chemistry. Springer, Cham. https://doi.org/10.1007/978-3-319-98947-1_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98947-1_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98946-4

  • Online ISBN: 978-3-319-98947-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation